As the Founder and CEO of Good Therapeutics, Inc., John Mulligan is at the forefront of innovation in the biopharmaceutical landscape, leveraging his extensive expertise in drug discovery, genetics, and molecular biology. With a rich background that includes pivotal roles in multiple drug discovery companies...
As the Founder and CEO of Good Therapeutics, Inc., John Mulligan is at the forefront of innovation in the biopharmaceutical landscape, leveraging his extensive expertise in drug discovery, genetics, and molecular biology. With a rich background that includes pivotal roles in multiple drug discovery companies and a synthetic biology venture, John has consistently demonstrated his ability to translate scientific insights into viable therapeutic solutions. At Good Therapeutics, he is leading a talented team focused on advancing their proprietary technology, which is designed to precisely regulate therapeutic activity. This innovative approach not only enhances the efficacy of treatments but also aims to minimize side effects, a crucial factor in the development of next-generation biopharmaceuticals.
John’s previous experience at Darwin Molecular, where he pioneered a novel method for identifying drug targets through human genetics, underscores his commitment to integrating cutting-edge science with practical applications in drug development. His strategic vision for Good Therapeutics includes expanding their current pipeline and exploring new therapeutic programs that harness the power of proteomics and cell biology. Under his leadership, the company is poised to make significant strides in addressing unmet medical needs, particularly in the realm of infectious diseases and other challenging health conditions.
With a strong foundation in entrepreneurship and technology transfer, John is adept at navigating the complexities of clinical trials and regulatory pathways, ensuring that innovative therapies move efficiently from concept to clinic. His passion for fostering start-ups and nurturing scientific talent further enhances Good Therapeutics' mission to revolutionize the way therapies are developed and delivered, ultimately improving patient outcomes in a rapidly evolving healthcare landscape.
